COVID19

The MORL is committed to providing outstanding and timely testing to enable you to care for your patients. During the COVID19 pandemic, MORL scientists are working in shifts to reduce exposure and promote physical distancing. We are therefore unable to keep all TATs but will prioritize sample analysis to ensure that needed results are available to you as soon as possible. If you have urgent need for specific results, please note this information on the requisition form and also email morl@uiowa.edu to leave a detailed explanation. Please provide your contact information so that we can contact you with questions.

Featured Content

  • Providing the most accurate clinically-driven interpretation of genetic variants in a timely manne
    Uncontrolled complement activity drives many diseases including two ultra-rare renal diseases. MORL provides a metric to follow a patient’s clinical course. MORL Clinical Testing Menu
  • Providing the most accurate clinically-driven interpretation of genetic variants in a timely manner MORL Clinical Diagnostic Services
  • The Molecular Otolaryngology and Renal Research Laboratories (MORL) is a CLIA approved, Joint Commission accredited diagnostic laboratory with a technical expertise in clinical genetic testing and interpretation. MORL Certifications and Licensure
  • What does it mean to get your testing done at the MORL? Testing at MORL
  • Working to increase our knowledge base of non-syndromic hearing loss and complement-mediated renal disease, including the development of new treatment options for both hearing loss, aHUS and C3G. Research at MORL
OtoSCOPE
TMA thumb
complement testing

Ordering Genetic Hearing Loss Testing

Ordering Genetic Renal Panel Testing

Ordering Complement Functional Testing
OtoSCOPE provides comprehensive genetic testing for all genes implicated in non-syndromic hearing loss and many types of syndromic hearing loss. An Usher Syndrome Panel is also available. Genetic Renal Panel screens patients diagnosed with thrombotic microangiopathies and C3 glomerulopathy. The next-generation sequencing panel includes analysis of 12 genes for single nucleotide variants as well as MLPA, which identifies copy-number variations in the CFH-CFHR5 genomic region. Comprehensive complement testing includes quantitating complement proteins and their cleavage products, measuring complement activity, and screening for autoantibodies.

What does it mean to get your testing done at the MORL?

  • Your results are discussed at a multidisciplinary meeting.
  • Your testing is performed in the Clinical Division of the MORL by scientists who lead the world in the human genetics of deafness and complement-mediated renal diseases.
  • Our testing is the most comprehensive clinical testing available.
Research Portal

Conferences

Molecular Biology of Hearing and Deafness (MBHD): May 18-21, 2021

C3G Educational Day for Nephrologists: April 18, 2020: Postponed due to COVID19

16th DDD/C3G Family Conference:
October 16, 2021 - Keep watching for more information